Novartis AG Net Profit Margin Growth & History (NVS)
Novartis AG's net profit margin was 25.61% for fiscal 2025.
View full Novartis AG company overviewNovartis AG annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 25.61% | +1.88 pp |
| 2024 | 2024-12-31 | 23.73% | −8.96 pp |
| 2023 | 2023-12-31 | 32.69% | +16.21 pp |
| 2022 | 2022-12-31 | 16.48% | −39.66 pp |
| 2021 | 2021-12-31 | 56.14% | +39.55 pp |
| 2020 | 2020-12-31 | 16.59% | −8.12 pp |
| 2019 | 2019-12-31 | 24.71% | −3.43 pp |
| 2018 | 2018-12-31 | 28.14% | +9.96 pp |
| 2017 | 2017-12-31 | 18.18% | +4.37 pp |
| 2016 | 2016-12-31 | 13.81% | — |
Novartis AG quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.83% | −6.80 pp |
| Q1 2026 | 2026-03-31 | 23.34% | — |
| Q4 2025 | 2025-12-31 | 17.38% | — |
| Q3 2025 | 2025-09-30 | 27.36% | — |
| Q2 2025 | 2025-06-30 | 28.63% | +2.69 pp |
| Q2 2024 | 2024-06-30 | 25.94% | +5.68 pp |
| Q2 2023 | 2023-06-30 | 20.26% | +7.00 pp |
| Q2 2022 | 2022-06-30 | 13.26% | −9.08 pp |
| Q2 2021 | 2021-06-30 | 22.34% | +5.89 pp |
| Q2 2020 | 2020-06-30 | 16.45% | −41.35 pp |
| Q2 2019 | 2019-06-30 | 57.80% | −10.58 pp |
| Q2 2018 | 2018-06-30 | 68.39% | +52.22 pp |
| Q2 2017 | 2017-06-30 | 16.17% | — |
Novartis AG net profit margin trends
Over the last five fiscal years, Novartis AG's net profit margin increased from 16.59% to 25.61%, a change of +9.03 percentage points. The latest reported quarter, Q2 2026, shows 21.83%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...